Chord Therapeutics

Chord Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with rare, life-threatening, and severely disabling diseases. We are advancing our lead candidate, CRD1, towards orphan drug designation for the treatment of neuromyelitis optica (NMO) and myasthenia gravis (MG). At Chord Therapeutics, we are committed to transforming the lives of patients with rare diseases, who often have no or only limited treatment options available. Our development programs are built on a well-understood history of active substances, supported by clinical trials and use in human patients. We carefully select new indications based on robust scientific rationale aligned with the mechanism of action of the drug in the selected disease. By repurposing molecules with well-established safety and pharmacology profiles for new indications, we significantly reduce risks for patients and increase the likelihood of successful development, bringing new therapeutic options to patients and healthcare providers.